This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
ProPublica
propublica.org
did:plc:k4jt6heuiamymgi46yeuxtpt
The gene therapy Zolgensma helped children born with a fatal disease grow up to run and play.
But the cost was stunning: $2M per dose.
While taxpayers and charities funded the drug’s early development, execs, venture-capital backers and a pharma giant have reaped the profits.
(Pub. Feb. 2025)
https://www.propublica.org/article/zolgensma-sma-novartis-drug-prices-gene-therapy-avexis?utm_campaign=propublica-sprout&utm_content=1783378380&utm_medium=social&utm_source=bluesky
2026-07-06T22:53:05.528Z